March 22, 2012 -- Femasys Inc., a medical device developer of women's healthcare solutions, announced an agreement with Bayer Yakuhin Ltd., Osaka, Japan, for exclusive distribution rights in Japan for Femasys' FemVue Saline-Air Device. This is the first device that allows physicians to quickly and effectively evaluate with ultrasound a woman's fallopian tubes, a critical component of her fertility assessment. The FemVue evaluation procedure can be performed reliably and safely (no radiation), in the physician's office or any facility with ultrasound, in a cost-effective and convenient procedure. Whether performing FemVue as part of an initial fertility work-up or to reconfirm fallopian tube status prior to other procedures, its innovative design allows for easy adoption into any practice.
"Our partnership with Bayer now provides physicians in Japan access to our FemVue Saline-Air Device for fallopian tube assessment as a first step in infertility diagnosis or as a part of fertility confirmation," stated Kathy Lee-Sepsick, president & CEO of Femasys Inc. "There is no better partner to introduce FemVue to the Japanese market than Bayer and we have ramped production accordingly to support the commercialization efforts underway."
Bayer Yakuhin Ltd., a wholly-owned subsidiary of the Bayer HealthCare Corporation, has marketing authorization from the Ministry of Health, Labor and Welfare (MHLW) to promote FemVue through their world-class sales channel. The FemVue Saline-Air Device has marketing clearance in the United States, Europe, Canada and Japan. FemVue is currently distributed in the United States by Norgenix, LLC.
For more information: www.femasys.com
January 29, 2026 
